Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical TrialAdrian Boswood, Philip Watson, María Josefa Fernández del Palacio et al.|Journal of Veterinary Internal Medicine|2016Cited by 318
International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL StudyPhilip R. Fox, Marie de Swarte, Michele Borgarelli et al.|Journal of Veterinary Internal Medicine|2018Cited by 152
Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in catsPhilip R. Fox, Daniel F. Hogan, Clark E. Atkins et al.|Journal of Veterinary Cardiology|2009Cited by 113
Multicenter Evaluation of Plasma N-Terminal Probrain Natriuretic Peptide (NT-pro BNP) as a Biochemical Screening Test for Asymptomatic (occult) Cardiomyopathy in CatsPhilip R. Fox, Mark A. Oyama, Clarke E. Atkins et al.|Journal of Veterinary Internal Medicine|2011Cited by 100
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC StudyAdrian Boswood, Philip Watson, María Josefa Fernández del Palacio et al.|Journal of Veterinary Internal Medicine|2017Cited by 78